Addex enters option agreement with sinntaxis for an exclusive license to intellectual property covering the use of mglu5 inhibitors in brain injury recovery

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, april 30, 2025 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with sinntaxis ab (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mglu5) inhibitors for the treatment of brain injury recovery.
ADXN Ratings Summary
ADXN Quant Ranking